About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414•Sihuan Pharmaceutical Holdings Group Ltd.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Advanced Solid Tumors

Interventions

KBP-5209

Locations

3

United States

Locations (3)

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, United States

Key Dates

Start Date

April 7, 2015

Primary Completion Date

November 26, 2019

Completion Date

November 26, 2019

Last Updated

March 4, 2022

Related Studies

RECRUITINGPhase 1/2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

RECRUITINGPhase 1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558

Advanced Solid Tumors

RECRUITINGPhase 1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399

HR+ Breast CancerTriple Negative Breast Cancer (TNBC)+5 more

RECRUITINGPhase 1/2

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

NCT04826341

HRD CancerSCLC+1 more

RECRUITINGPhase 1/2

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

NCT06819735

Advanced Solid Tumors

RECRUITINGPhase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819

Advanced Solid TumorsHER2 Mutation

View all related studies

Sponsors

Lead Sponsor

Sihuan Pharmaceutical Holdings Group Ltd.

Collaborators

Covance
XuanZhu Pharma Co., Ltd.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions